Type Size

    Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss

    The authors examined the function of IL-20 in osteoclastogenesis and the therapeutic potential of an anti–IL-20 monoclonal antibody 7E for treating osteoporosis.  They found that IL-20 mediated osteoclastogenesis by up-regulating the receptor activator of NF-κB (RANK) expression in osteoclast precursor cells and RANK ligand (RANKL) in osteoblasts. In addition, 7E treatment completely inhibited osteoclast differentiation induced by macrophage colony-stimulating factor (M-CSF) and RANKL in vitro and protected mice from OVX-induced bone loss in vivo.


    Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS